WASHINGTON– Low HDL cholesterol does not increase the risk of coronary heart disease when LDL cholesterol and triglyceride levels are normal, according to an analysis from the <link...
WASHINGTON – Marital status plays an underappreciated role in heart failure prognosis.
Indeed, having a life partner was independently associated with a 12% reduction in the risk of all-cause...
WASHINGTON – The controversial cardiovascular risk estimator introduced in the current American College of Cardiology/American Heart Association risk-assessment guidelines demonstrated "moderate...
WASHINGTON – The off-label use of novel oral anticoagulants for stroke prevention in patients with valvular atrial fibrillation has climbed steeply since the drugs reached the marketplace, mirroring...
WASHINGTON – A novel pharmacologic approach to the prevention of ischemic events in patients with stable coronary heart disease failed to reduce the combined risk of cardiovascular death, acute...
WASHINGTON – "We’re at the dawn of an era of biological therapeutics in cardiology," Dr. Peter Libby, chief of cardiovascular medicine at the Brigham and Women’s Hospital in Boston, told us...
WASHINGTON – Far from being doomed after the failure SYMPLICITY HTN-3, renal denervation for refractory hypertension will continue to be explored. But it can’t go very far without finding a way to...
WASHINGTON – Apixaban yields the great medical cost savings of the three novel oral anticoagulants available as alternatives to warfarin for stroke prevention in patients with nonvalvular atrial...
WASHINGTON – Bariatric surgery combined with intensive medical therapy had a significantly greater impact on glycemic control, compared with medical therapy alone, in a <link...
WASHINGTON – Evolocumab, an investigational fully human monoclonal antibody, was associated with markedly greater LDL cholesterol reductions than ezetimibe in a phase III clinical trial of...